logo-loader
RNS
viewVerona Pharma

Verona Pharma plc: PDMR Dealing

Verona Pharma plc: PDMR Dealing

LONDON, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 8, 2019, Dr. David Ebsworth, Chairman of the Company, purchased a further 60,000 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 50 pence per Ordinary Share and a total purchase price of £30,000.  This purchase brings the total purchases made by Dr. Ebsworth during 2019 to approximately £80,000.

Following the acquisition, Dr. Ebsworth will have an interest in the Company of 295,387 Ordinary Shares, representing 0.28% of the Company’s issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1Details of the person discharging managerial responsibilities/person closely associated
a)NameDavid Ebsworth
2Reason for the notification
a)Position/statusChairman
b)Initial notification/AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameVerona Pharma plc
b)LEI
213800EVI6O6J3TIAL06


4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
a)Description of the financial instrument, type of instrumentOrdinary Shares of 5 pence each 
 Identification codeGB00BYW2KH80 
b)Nature of the transactionDavid Ebsworth purchased 60,000 Ordinary Shares 
    
c)Price(s) and volume(s)Price(s)Volume(s)
  50 pence per Ordinary Share60,000 Ordinary Shares
    
d)Aggregated informationN/A 
 -  Aggregated volume  
 -  Price  
e)Date of the transaction8 August 2019 
f)Place of the transactionLondon Stock Exchange, AIM 

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
[email protected]
  
N+1 Singer
(Nominated Adviser and UK Broker)
Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer / Iqra Amin (Corporate Finance) 
Mia Gardner (Corporate Broking) 

Quick facts: Verona Pharma

Price: 46.25

Market: AIM
Market Cap: £48.71 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE